Summary.-A prospective trial with concurrent controls was designed to assess the effects of specific active immunotherapy in patients receiving intermittent cytotoxic chemotherapy (DTIC+Vincristine) as an adjuvant to surgery in Stage IIB malignant melanoma. The treated group received monthly irradiated allogeneic melanoma cells and BCG, and the controls BCG only. Sixteen patients in the treatment arm had a median relapse-free interval of 5 months, compared to 8 months in 12 controls given chemotherapy and BCG, and because of this we felt that continuation of the study was unjustified on ethical grounds. Although all the controls who relapsed did so at distant sites, 7/11 patients given specific active immunotherapy relapsed initially within the lymphatic drainage area of the primary tumour. The median intervals from starting treatment to relapse at distant sites, and the median survival were identical in the 2 groups.
CLINICAL involvement of the regional lymph nodes (Stage IIB) in malignant melanoma carries a poor prognosis. The mainstay of treatment remains surgical excision of the nodes en bloc, but although this produces good local control of the disease (Veronesi et al., 1977; McNeer and Cantin, 1967) most patients eventually die from distant metastases which were clinically undetectable at the time of surgery. Improvement in long-term survival therefore requires the suppression of occult metastases by some form of systemic therapy deployed as an adjuvant to surgery. Disseminated malignant melanoma responds poorly to chemotherapy. DTIC remains the most active single agent, producing an objective regression rate of around 20%, although most of these regressions are partial and transient (Luce, 1972) . Combinations of drugs, some including DTIC, are probably no more active than DTIC alone, and produce greater toxicity. Attempts have been made to improve the response to chemotherapy by supplementing it with various types of immunotherapy, and we have treated an uncontrolled series of 59 patients with disseminated malignant melanoma, using a combination of DTIC and specific active immunotherapy with irradiated allogeneic melanoma cells (Hedley, McElwain and Currie, 1977) . Although there was no evidence of an effect on survival, the incidence of objective regressions in patients with early dissemination (i.e. confined to skin, lymph nodes or lungs) was distinctly higher than historical or literature controls; an observation similar to that of Newlands et al. (1976 and control arms are identical. We felt obliged to abandon the study on ethical grounds, in view of the very short relapsefree interval in the patients receiving irradiated allogeneic tumour cells (5 months). Although conventional statistical methods do not show that this is significantly shorter than that in the control arm (8 months) it was certainly no better, and we did not feel justified in continuing the study in order to prove the existence of a statistically significant harmful effect. The absence of any beneficial effects and the possibility of harm attributable to the use of irradiated melanoma cells is reminiscent of the recent smaller study published by Mclllmurray and his colleagues (1977) . Although their study and ours differ in many respects the conclusions are similar.
The use of active immunotherapy as an adjuvant in Stage II malignant melanoma has so far produced conflicting results. Concurrently controlled studies such as that reported by Pinsky et al., (1976) show that BCG immunotherapy is without effect. Other series reporting evidence of clinical benefit (Gutterman, Mavligit and McBride, 1973) were performed without concurrent controls, and must therefore be regarded with some suspicion (Editorial, Br. med. J. 1976).
The relapse-free intervals and survival times in our patients are not strictly comparable with those obtained by many other authors (except perhaps Mclllmurray et al., 1977) since patient selection was different. None of our patients had received earlier prophylactic lymph-node surgery and all of them presented with clinically detectable lymph-node metastases. However, the patterns of relapse in our patients are intriguing. Radical block dissection for Stage IIB melanoma is usually associated with relapse at distant sites (Veronesi et al., 1977) and this was the case in all our control patients. The very high incidence of local relapse in our patients receiving irradiated allogeneic tumour cells is statistically significant, and suggests that the immunization procedure is changing the biological behaviour of the tumour. Although we do not have comprehensive data on the number of regional lymph nodes found to be involved at block dissection, we do not believe that such a variable, or variations in surgical technique, can be responsible, since our patients were referred by several different centres, and there is no indication of bias in the allocation to treatment or control arms according to the origin of the patients.
The promotion of early local recurrence without any effect on distant recurrence or survival is an observation ripe for immunological speculation. It is conceivable, for instance, that depot immunization with tumour cells plus BCG might act as a focus for trapping specifically allergized effector cells, and thus may deplete other sites such as the local drainage area of the excised lymph nodes. Some form of antigenic overload, such as that demonstrated by Vaage (1973) in experimental animals, is also a possibility. No such speculations would be complete nowadays without mentioning the possible generation of specific suppressor T cells.
Since we do not feel justified in continuing this form of treatment in our patients, opportunities for examining these possibilities have vanished. However, studies in progress at other centres could provide an opportunity for evaluating such possible explanations.
The shape and time course of the survival curves obtained from this study are remarkably similar to those previously obtained in patients with disseminated disease confined to skin, lymph nodes or lungs (Hedley et al., 1977) . This similarity in biological behaviour may have implications for the proponents of adjuvant cytotoxic chemotherapy. Since patients with "early" dissemination are in this respect indistinguishable from patients with clinically undetectable disease, any statements that the disease in the latter patients is in any way more amenable to ablation with systemic therapy must be regarded with suspicion. Furthermore, this study may be yet another confirma-tion of what seems to be a general principle: that adjuvant treatment can only be expected to raise the cure rate for a particular tumour when that treatment is capable of producing a high incidence of complete regression in patients with disseminated disease. The failure of a chemotherapy-immunotherapy protocol as an adjunct to surgery in Stage IIB malignant melanoma reflects its failure in disseminated disease.
